Updating results

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis: care and management (update)

In development [GID-NG10127] Expected publication date: 25 August 2021

NICE guideline In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

In development [GID-TA10222] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483) [ID1559]

In development [GID-TA10516] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

In development [GID-TA10417] Expected publication date: 21 April 2021

Technology appraisal guidance In development

Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10143] Expected publication date: 12 February 2020

NICE guideline In development

Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Technology appraisal guidance In development

Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

In development [GID-TA10151] Expected publication date: TBC

Technology appraisal guidance In development

Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Technology appraisal guidance In development

Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating recurrent glioblastoma [ID998]

In development [GID-TA10126] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Technology appraisal guidance In development

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]

In development [GID-TA10008] Expected publication date: TBC

Technology appraisal guidance In development

Generalised anxiety disorder - quetiapine [ID347]

In development [GID-TAG421] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Technology appraisal guidance In development

Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Technology appraisal guidance In development

Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

In development [GID-TA10018] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

In development [GID-TAG425] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

In development [GID-TAG424] Expected publication date: TBC

Technology appraisal guidance In development

Obesity - phentermine (with topiramate) [ID543]

In development [GID-TAG439] Expected publication date: TBC

Technology appraisal guidance In development

Constipation (opioid induced) - methylnaltrexone bromide [ID700]

In development [GID-TA10003] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

In development [GID-TAG494] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell) - cetuximab [ID9]

In development [GID-TAG395] Expected publication date: TBC

Technology appraisal guidance In development

Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Technology appraisal guidance In development

Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Technology appraisal guidance In development

Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

In development [GID-TAG440] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]

In development [GID-TAG444] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute) - serelaxin [ID673]

In development [GID-TAG454] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Technology appraisal guidance In development

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

In development [GID-TA10144] Expected publication date: TBC

Technology appraisal guidance In development